PD-1 Ligand Expression in Epithelial Thyroid Cancers: Potential Clinical Implications

The new immunotherapy targeting the programmed cell death 1 (PD-1) receptor and its cognate ligand PD-L1 has renewed hopes of eradicating the most difficult human cancers to treat. Among these, there are the poorly differentiated and anaplastic thyroid cancers, unresponsive to all the therapies curr...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2019-03, Vol.20 (6), p.1405
Main Authors: Ulisse, Salvatore, Tuccilli, Chiara, Sorrenti, Salvatore, Antonelli, Alessandro, Fallahi, Poupak, D'Armiento, Eleonora, Catania, Antonio, Tartaglia, Francesco, Amabile, Maria Ida, Giacomelli, Laura, Metere, Alessio, Cornacchini, Nicola, Pironi, Daniele, Carbotta, Giovanni, Vergine, Massimo, Monti, Massimo, Baldini, Enke
Format: Article
Language:English
Subjects:
Apoptosis
Arthritis
Autoimmune diseases
Cell activation
Cell death
Chromosomes
Chronic conditions
CTLA-4 protein
Cytotoxicity
Diabetes mellitus
Encephalomyelitis
Immune system
Immunoregulation
Inflammatory bowel diseases
Interleukin 10
Intestine
Kinases
Lymphocytes
Lymphocytes T
Myasthenia
Myasthenia gravis
Natural killer cells
Neuromuscular junctions
PD-1 protein
Review
Rheumatoid arthritis
Suppressor cells
Systemic lupus erythematosus
Thyroid cancer
Tryptophan 2,3-dioxygenase
Vascular endothelial growth factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The new immunotherapy targeting the programmed cell death 1 (PD-1) receptor and its cognate ligand PD-L1 has renewed hopes of eradicating the most difficult human cancers to treat. Among these, there are the poorly differentiated and anaplastic thyroid cancers, unresponsive to all the therapies currently in use. In the present review we will summarize information regarding the expression of PD-L1 in the different thyroid cancer histotypes, its correlation with clinicopathological features, and its potential prognostic value. Then, we will evaluate the available data indicating the PD-1/PD-L1 axis as a promising target for thyroid cancer therapy.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms20061405